The asthma and COPD drugs market size was valued at a USD 37.22 billion in 2022 and it is anticipated to reach USD 61.54 billion by 2032, with an expanding 5.01% of CAGR from 2023 to 2032.
The asthma and COPD drugs market size was valued at a USD 37.22 billion in 2022 and it is anticipated to reach USD 61.54 billion by 2032, with an expanding 5.01% of CAGR from 2023 to 2032.
Download a sample of segments affecting Asthma and COPD Drugs Market growth in detail @ Get a Asthma and COPD Drugs Market Sample
Asthma and COPD are common lung disorders characterized by excessive airway constriction, which makes breathing difficult.
Asthma involves bronchial narrowing and difficulty breathing, often accompanied by symptoms like shortness of breath, chest tightness or pain, and wheezing during exhalation. Chronic Obstructive Pulmonary Disease (COPD) is a group of respiratory disorders, including emphysema and chronic bronchitis.
Diagnosis of asthma and COPD typically involves X-ray imaging, nitric oxide testing, and sputum examination. Bronchoconstriction, a common symptom of both conditions, can be managed with corticosteroids, anticholinergic drugs, and long-acting beta-agonists. Asthma patients may experience sudden bronchoconstriction, known as an asthma attack, which can be treated with bronchodilators delivered via specially designed pumps for immediate relief.
Functional pulmonary testing, such as spirometry and body-plethysmography, is crucial for diagnosing, determining severity, and managing both asthma and COPD.
COPD ranks as the third-leading cause of death worldwide, with 3.23 million deaths recorded in 2019, according to the World Health Organization (WHO). Over 80% of these deaths occurred in low and middle-income countries (LMICs). The global geriatric population is a significant factor in market growth, with approximately 727 million people aged 65 or older in 2020, projected to more than double by 2050. The proportion of the population aged 65 and above is expected to increase from 9.3% in 2020 to 16% by 2050.
Recent research suggests that children who have experienced trauma, such as divorce, the death of a parent, or domestic violence, are more likely to develop asthma than other children.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Impact of COVID-19 on Asthma and COPD Drug Market
A study published in the Journal of Medical Virology in March 2021 by Hashim T. et al. highlighted the negative impact of the COVID-19 pandemic on the mental health of asthmatic patients worldwide, especially during the initial stages of the pandemic in 2020. Despite the strict adherence of many asthmatic patients to preventive measures and quarantine rules to avoid infection, concerns arose due to the susceptibility of asthmatic patients to the disease. The primary targets of the SARS-CoV-2 virus are the lungs and lung parenchyma, raising concerns about outcomes in patients with chronic respiratory diseases such as asthma.
Viral respiratory infections are common aggravation triggers in asthma and COPD patients, as they induce proinflammatory cytokines within airway epithelial cells, such as IL-1, IL-6, and IL-11. While it remains uncertain whether COVID-19 may exacerbate asthma and COPD, the initiation of similar pro-inflammatory cytokines (including IL-1 and IL-6) and subsequent lung inflammation in COVID-19 suggest the possibility of exacerbation in these patients. Therefore, the primary goal of COVID-19 therapy in asthma and COPD patients is to reduce the risk of exacerbation, which could further affect pulmonary reserve. In cases where COVID-19 worsens asthma, the dose of ICS can be increased to four times the baseline.
Influencers Driving Market Growth
The global increase in asthma incidence is a significant driver of the asthma and COPD drug markets. According to a report published by the Global Asthma Network in 2020, asthma kills around 1000 people every day and affects 339 million people worldwide. Additionally, rising public awareness of respiratory diseases and innovation in asthma treatment by manufacturers and researchers contribute to market expansion. Government initiatives aimed at treating and improving the lifestyle of asthma and COPD patients also bolster market growth, along with the increased number of hospitals and developed healthcare infrastructure.
For customization of the report, we can include specific regional analyses, detailed market segmentation, and insights into emerging trends and innovations in asthma and COPD treatments @ Get Customization in Asthma and COPD Drugs Market
The rise in tobacco smoking habits and air pollution also contributes to the growth of the asthma and COPD drugs market. However, the increasing cost of treatment for asthma and COPD is expected to restrain market growth.
Harnessing the Power of Probiotics for Asthma Treatment
Probiotics are becoming increasingly popular in the treatment of asthma and COPD, offering potential benefits to patients. By enhancing the host immune system through the gut ecosystem, probiotics hold promise in managing allergic conditions like asthma. For example, Activated Probiotics, an Australian company specializing in premium probiotic products, announced in November 2020 its expansion into developing probiotic treatments for asthma.
Bioelectric Medicine: A New Frontier for Asthma Patients
Bioelectric medicines are emerging as a novel approach for managing asthma, with companies in the anti-asthmatics and COPD drugs markets leading the way. This innovative field utilizes miniaturized, implantable devices to modify electrical signals along nerves in the body, addressing irregular impulses seen in many illnesses. In July 2020, ElectroCore, Inc., a US-based bioelectronic medicine company, received FDA approval for a nerve stimulator aimed at asthma patients, particularly those at risk from the novel coronavirus.
Stay ahead in the growing asthma and COPD drugs market - Buy our report now to capitalize on emerging opportunities and insights @ Buy Now Asthma and COPD Drugs Market Report (2023 - 2032)
Market Scope and Categorization
The Impact of Asthma: By Disease
Asthma is a potentially life-threatening condition that disrupts regular breathing and stands as one of the most prevalent diseases worldwide. It’s a chronic ailment that involves the constriction and dilation of the air passages in the lungs, leading to episodes of breathlessness, bronchospasm, and reversible airflow obstruction. Moreover, the significant surge in cigarette consumption exacerbates asthma symptoms. Additionally, the upsurge in industrialization has contributed to a rise in asthma cases, which is likely to drive the demand for asthma medication in the coming years.
The Impact of Asthma: By Medication Class
The asthma and COPD drug market in 2021 is witnessing a significant dominance of combination drugs. The trend of utilizing a mix of medications to treat various disorders has been steadily rising over the past decade. Research studies indicate that patients suffering from COPD and asthma can now reap benefits from combination drugs.
Moreover, the inhaled corticosteroids (ICS) segment is projected to be the fastest-growing segment in the asthma and COPD drugs market in 2021. Inhaled corticosteroids (ICS) play a crucial role in preventing asthma attacks and improving lung function. They are also effective in treating other lung disorders like COPD. In comparison to other drug types, inhaled corticosteroids (ICS) have shown high effectiveness in asthma treatment.
The Impact of Asthma: By Distribution Channel
In 2021, the general pharmacies distribution channel took the lead, constituting 65.3% of the entire anti-asthmatics and COPD drugs market. Looking ahead, the online retailer’s distribution channel is projected to witness the most rapid growth. This shift reflects changing consumer preferences and advancements in technology, with more individuals opting for the convenience and accessibility offered by online platforms for purchasing medications. As online retail continues to expand, driven by factors such as ease of comparison, home delivery, and digital prescriptions, it is expected to carve a significant share of the market previously dominated by traditional pharmacies. This transformation underscores the evolving landscape of pharmaceutical distribution channels, with online retailers poised to play a pivotal role in meeting the demands of consumers seeking efficient and convenient healthcare solutions.
The Impact of Asthma: By Route of Administration
The market for drugs treating asthma and chronic obstructive pulmonary disease (COPD) is segmented by administration routes, including inhaled, intravenous, subcutaneous, and oral. As of 2021, the inhaled route held the largest share, comprising 73.1% of the total market for anti-asthmatic and COPD drugs. This dominance reflects the effectiveness and convenience of inhaled medications in managing respiratory conditions like asthma and COPD. Inhaled drugs offer targeted delivery directly to the lungs, minimizing systemic side effects and providing rapid relief for patients. As such, they remain the preferred choice for many healthcare providers and patients alike.
The Impact of Asthma: By Region
Over the projected period, North America is expected to lead the Asthma and COPD drugs market, largely due to the increasing prevalence of these conditions, particularly among the aging population. With approximately 25 million Americans affected by asthma, representing about 8% of adults and 7% of children, the demand for effective medications is substantial. Moreover, ongoing research and development efforts, coupled with the presence of major market players, contribute to North America’s dominance. In contrast, Europe is forecasted to witness the fastest growth, with the United Kingdom as a key player. The region’s emphasis on raising awareness about asthma and COPD, as evidenced by initiatives like the United Action for Allergy and Asthma, is expected to drive market expansion significantly. This growing awareness, combined with the rising prevalence of respiratory diseases, is likely to propel the demand for asthma and COPD drugs in Europe in the coming years.
Recent Developments in Respiratory Medications
- Glenmark Pharmaceuticals Launches Tavulus Dry Powder Inhaler in Spain: Glenmark Pharmaceuticals introduced the Tavulus dry powder inhaler (DPI) in Spain in October 2021 for treating chronic obstructive pulmonary disease (COPD).
- ChiesiFarmaceuticiSpA Initiates PILASTER Study: ChiesiFarmaceuticiSpA commenced the PILASTER study in June 2021 to evaluate the efficacy and safety of two doses of CHF6001 (Tanimilast) as an add-on to maintenance triple therapy in COPD patients.
- European Commission Approves Nucala for Severe Eosinophilic Asthma: In August 2018, the European Commission approved Nucala for diagnosing severe eosinophilic asthma in young patients, addressing a significant unmet need in Europe. This approval is particularly crucial as treatment options for severe asthma in children and adults are limited in the region.
- EMA Approves New Indication for Trelegy Ellipta: In February 2020, the European Medicines Agency (EMA) approved GlaxoSmithKline PLC’s regulatory submission to expand the indication of Trelegy Ellipta, a once-daily single-inhaler treatment, for adult asthma.
- FDA Approves Cipla’s Generic Asthma Inhaler in Response to Shortages: In April 2020, the US Food and Drug Administration (FDA) approved Cipla’s generic asthma inhaler, a generic version of the albuterol inhaler, to address shortages caused by the COVID-19 pandemic.
Major Rivals in the Market for COPD and Asthma Drugs Include:
- GlaxoSmithKline plc
- AstraZeneca plc
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Novartis AG
Browse More Insights of Towards Healthcare:
- AI in Cancer Diagnostics Market Size Report 2023 - 2032
- Smart Healthcare Market Size Report 2023 - 2032
- Hospital Services Market Size Report 2023 - 2032
- Acne Treatment Market Size Report 2023 - 2032
- Newborn Eye Imaging Systems Market Size Report 2023 - 2032
- Precision Oncology Market Size Report 2023 - 2032
- Non-invasive Aesthetic Treatments Market Size Report 2023 - 2032
- Asthma Treatment Market Size Report 2023 - 2032
- Cold Storage Market Size Report 2023 - 2032
- Artificial Intelligence (AI) in Genomics Market Report 2023 - 2032
Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5011
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Browse our Brand-New Journals:
https://www.towardspackaging.com
https://www.towardsautomotive.com
Web: https://www.precedenceresearch.com
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Get Our Freshly Printed Chronicle: https://www.healthcarewebwire.com